NCT00161655

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

Conditions

• Psoriasis
• Arthritis, Psoriatic

Interventions

Type	Name	Description
DRUG	Etanercept
DRUG	Methotrexate

Timeline

• Start date: 2005-04-01
• Primary completion: 2006-08-01
• Completion: 2006-12-01
• First posted: 2005-09-12
• Last updated: 2009-09-28

Locations

8 sites across 4 countries: Denmark, Finland, Norway, Sweden